Shintaro Kanda

9PUBLICATIONS
31CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Medical physicsPredictive and prognostic markersImmunology not elsewhere classifiedMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Aug 27, 2026
Clinical Outcomes of Second-Line Amrubicin and Platinum-Based Doublet Chemotherapy in Patients with Extrapulmonary Neuroendocrine Carcinoma: A Multicenter Retrospective Study.

|Mar 31, 2025
Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non-Small Cell Lung Cancer Harboring EGFR Mutation.

Shintaro Kanda, Seiji Niho, Takayasu Kurata

|May 03, 2023
Successful resection after first-line lenvatinib therapy in an advanced thymic carcinoma.

Masatoshi Shimura, Kentaro Miura, Tomonobu Koizumi

|Mar 25, 2023
A case of mediastinal mesenchymal tumor with pericytic neoplasm feature that responded to radiation therapy.

Miho Muramoto, Shintaro Kanda, Takashi Kobayashi

|May 26, 2022
Predictive value of post-treatment C-reactive protein-to-albumin ratio in locally advanced non-small cell lung cancer patients receiving durvalumab after chemoradiotherapy.

Taisuke Araki, Kazunari Tateishi, Masamichi Komatsu

|Feb 14, 2022
Association of lung immune prognostic index with survival outcome in advanced thymic carcinoma patients treated with palliative intent chemotherapy.

Taisuke Araki, Kazunari Tateishi, Masamichi Komatsu

Pageof 2

Frequent Collaborators

6 joint publications

Tomonobu Koizumi

2 joint publications

Yuichiro Ohe

2 joint publications

Yutaka Fujiwara

2 joint publications

Taisuke Araki